Key Takeaways
- Volume-led 40-50% revenue growth guided for FY26: Management expects topline to jump on the back of Pakhajan ramping to 65-70% utilization, with all customer approvals now secured after a two-quarter delay.
- Margins guided cautiously at 17-19% EBITDA: Despite gross margins spiking to 43.1% this quarter, management is anchoring expectations low, citing geopolitical pricing uncertainty and a deliberate choice to avoid over-promising.
- Pakhajan hits monthly EBITDA breakeven: The new plant is at ~50% utilization and has stopped losing money at the operating level, validating the investment thesis even as depreciation and interest weigh on PAT.
- Inventory doubled and needs to normalize: Finished goods stockpiled for customer validations will unwind by September, releasing an expected ₹40 crores in working capital, a key cash flow catalyst to watch.
- What to watch next quarter: Whether the promised inventory unwind materializes by September, the pace of the utilization ramp toward 70%, and any revision to the deliberately conservative margin guidance.
Pakhajan Ramp-Up & Customer Approvals
- Two-quarter delay now resolved: The approvals cycle ran behind schedule, but management states all customer and end-customer approvals are now in place, converting business interest into actual orders.
- Utilization trajectory: Currently at ~50%, with a target of 65-70% for the full year FY26, implying a steep second-half ramp that could hit 90% in Q4.
- EBITDA breakeven achieved: On a monthly basis, Pakhajan is no longer a drag at the operating level, though depreciation and interest from the new plant suppressed full-year PAT to ₹6 crores.
- Capacity expansion already planned: Marginal capacity additions for select high-growth products are underway within existing buildings; a third building may be considered in FY27 if demand warrants.
- OEM vs aftermarket blind spot: Management cannot quantify what portion of Pakhajan sales ends up in OEM applications, stating it has no OEM customers directly and cannot track downstream use.
Parag Jhaveri: "We were expecting a lot of approvals, lot of business in last year. We are running behind almost by 2 quarters, but I think we have come to the end of that challenge of approval getting the business, so business interest has started converting into the actual business and that gives us confidence to give policy guideline of achieving the 40%-50% of topline growth."
Revenue Growth & Volume Dynamics
- Volume is the entire growth story: Management was explicit that pricing assumptions are flat, so the 40-50% FY26 revenue growth guidance rests entirely on volume expansion from Pakhajan.
- FY25 base built on 20% volume growth: The year closed at ₹668 crores topline, with volume improvement offsetting subdued pricing to deliver a 19% EBITDA margin in Q4.
- FY27 momentum claimed early: Management expressed confidence in sustaining 40-50% growth into FY27, citing space for further expansion and CAPEX coming online, though this is a vague timeline statement with no conditions attached.
- Pricing environment remains soft: No significant price increases are visible globally, and projections are built purely on current market prices with no upward or downward assumptions.
- Crude oil is not a pricing lever: Softer crude has no impact on product pricing, which is driven by demand-supply dynamics specific to the specialty chemicals the company produces.
Margin Outlook & Gross Margin Sustainability
- Q4 gross margin spike is not the new normal: The 43.1% gross margin, up from 36.9% YoY, was driven by a favorable product mix and niche products; management pegs 40% as the sustainable long-run level.
- EBITDA guidance deliberately conservative: The 17-19% band for FY26 reflects geopolitical pricing uncertainty and a conscious choice to stay grounded; management will revise upward only if it can deliver, not on hope.
- Economies of scale are the margin lever: As Pakhajan utilization climbs from 50% toward 70%, fixed cost absorption should improve, but management is not yet quantifying the uplift.
- Analyst pushback on margin guidance: When asked to provide EBITDA margin at 70% utilization or a blended FY26 figure, management declined to raise the band, sticking to 17-19% despite the implied operating leverage.
Parag Jhaveri: "Let me be a more cautious effort rather than taking an highly over confident efforts, so we want to remain firmally on grounded, not to give a wrong guidance which will cannot be fulfilled, so achievable guidance on a longer term with the current market situation and current geopolitical situation is wiser to give in 17%-19% if you see that we are able to pull out all kind of things and we will be able to improvise, we will revise our guidance by the media, but for the beginning of the year, I want to be cautious, I don't want to go highly into that overdrive."
Balance Sheet & Working Capital
- Inventory doubled year-on-year: The buildup is finished goods produced for customer validations, not work-in-process or customer-specific stock; all product is standard quality supplied globally.
- ₹40 crores cash release expected: As inventory normalizes to a 110-115 day target by FY26, management expects to free up approximately ₹40 crores from working capital.
- Normalization timeline: Inventory should come down drastically by the September quarter, with the full-year target of 110-115 days achievable within FY26.
- Debt reduction path: Current debt of ~₹470 crores is expected to fall to ~₹450 crores in FY26 and ~₹400 crores in FY27, targeting a debt-to-EBITDA ratio of 3.5x.
- ₹125 crores equity raise deployed: Preferential issuance proceeds are earmarked for industrial segment opportunities and long-term debt reduction.
- FY28 debt data unavailable: When asked for FY28 debt projections, management directed the analyst to email the new CFO separately.
US Market, Tariffs & Competitive Landscape
- Tariff pass-through is working: The company can generally pass on costs to US customers because the US does not produce all the required chemistry; customers are accepting revised prices.
- Some segments in wait-and-watch mode: Not all customers are moving at the same speed, with certain segments pausing to assess the tariff environment before committing.
- Benefit quantification is premature: Management cannot yet estimate how much India's favorable tariff position relative to China will benefit FY26 revenue.
- US warehouse now operational: The facility, live since March 2025, improves service efficiency for the US market, which is a key export destination.
- China's presence acknowledged but not sized: Management admits China likely has producers in the same chemical space and may be present in the US market, but offered no specific insight into the competitive dynamics.
Parag Jhaveri: "Well, as you know that US don't produce all the chemistry, so the chemistry which they don't produce so we are able to pass it on... So we generally pass it on to customers and so far we have seen that customers are accepting our new revised prices."
New Products, CAPEX & Disclosure Changes
- Four of five new product lines installed: Out of the ₹5,000 crores addressable market opportunity discussed in Q1 FY25, four lines are in place and the fifth is work-in-progress, tied to research CAPEX.
- FY26 CAPEX of ₹75-100 crores: The majority goes to capacity expansion at Pakhajan, with a portion allocated to an R&D facility; completion is expected by early Q4 FY26, with revenue impact visible from Q1 FY27.
- Fixed asset turns target pushed out: Management expects 3x returns on fixed assets only by FY27 at the earliest, and possibly as late as FY28.
- Capacity chart deliberately removed: The company has stopped disclosing installed capacity in tonnes, preferring to guide on revenue and performance instead; when pressed for capacity addition figures, management declined.
- China-sourced raw material question deflected: When asked if the 10-15% of Pakhajan raw material sourced from China could be substituted, management answered only "Yes and No" without elaboration.
Parag Jhaveri: "I think now we are not keen to give you the overall capacity. We will always give guidance on the revenue side rather than the capacity of installed capacity. So hence you must have observed that this year investor presentation also, we removed the capacity's chart so we are not comfortable to give the capacity what we have rather than we will be more happy to talk about the revenue side and also performance side."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 40-50% increase in topline | FY26 |
| Pakhajan utilization | 65-70% for the full year | FY26 |
| EBITDA margin | Maintain 17-19% band | FY26 |
| Inventory normalization | Drastic reduction to 110-115 days target | By September quarter |
| Working capital release | ~₹40 crores freed from inventory | FY26 |
| Debt reduction | Debt down to ~₹450 crores; debt/EBITDA at 3.5x | FY26 |
| Debt reduction | Debt down to ~₹400 crores | FY27 |
| CAPEX completion | ₹75-100 crores spend finished, impact in Q1 FY27 | Early Q4 FY26 |
| Fixed asset turns | 3x returns on fixed assets | FY27 earliest, possibly FY28 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue from operations | ₹182.8 cr, +8% YoY |
| Revenue from operations (FY25) | ₹668 cr, +13% YoY |
| EBITDA | ₹35.6 cr, margin 19% |
| EBITDA (FY25) | ₹118 cr, margin 17% |
| PAT | ₹5 cr |
| PAT (FY25) | ₹6 cr, impacted by depreciation and interest on Pakhajan plant |
| Gross margin | 43.1%, up from 36.9% in Q4 FY24 |
| Volume growth | 20% YoY |
| Exports share | 67% of total revenue |
| Industrial segment share | 85% of Q4 revenue, 83% for FY25 |
| Consumer segment share | 15% of Q4 revenue, 17% for FY25 |
| Pakhajan capacity utilization | ~50%, target 70% by Q4 FY26 |
| US revenue share | 20%-22% of combined revenue |
| Average realization | ₹375-400 per kg |
| Gross debt | ₹470 cr, expected to reduce to ~₹450 cr by FY26-end |
| FY26 revenue growth guidance | 40-50% |
| FY26 EBITDA margin guidance | 17%-19% |
| FY26 capex outlay | ₹75-100 cr, 30-40% for R&D facility |
| Working capital days | >200 days, target 110-115 days by FY26-end |
| Inventory | ~₹260 cr, expected to normalize by September quarter |
| Debt-to-EBITDA ratio target | 3.5x by FY26 |
| Equity raised | ₹125 cr via preferential issue |
| Pakhajan RM sourcing | 70% domestic, 30% import; of imports, 10-15% from China |
| FY27 debt expectation | ~₹400 cr |
| Infrastructure capex incurred | ₹240 cr out of ₹480 cr total spend |
| Asset turns expectation | 3x returns earliest by FY27, could extend to FY28 |